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Abstract
Objectives. Bacillus Calmette–Guerin (BCG) vaccination has been
implicated in protection against severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) and as a non-specific immunisation
method against the virus. We therefore decided to investigate T-
cell and B-cell epitopes within the BCG-Pasteur strain proteome
for similarity to immunogenic peptides of SARS-CoV-2. Methods.
We used NetMHC 4.0 and BepiPred 2.0 epitope prediction
methods for the analysis of the BCG-Pasteur proteome to identify
similar peptides to established and novel SARS-CoV-2 T-cell and B-
cell epitopes. Results. We found 112 BCG MHC-I-restricted T-cell
epitopes similar to MHC-I-restricted T-cell SARS-CoV-2 epitopes and
690 BCG B-cell epitopes similar to SARS-CoV-2 B-cell epitopes. The
SARS-CoV-2 T-cell epitopes represented 16 SARS-CoV-2 proteins,
and the SARS-CoV-2 B-cell epitopes represented 5 SARS-CoV-2
proteins, including the receptor binding domain of the spike
glycoprotein. Conclusion. Altogether, our results provide a
mechanistic basis for the potential cross-reactive adaptive
immunity that may exist between the two microorganisms.
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INTRODUCTION
The current pandemic caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2)
has led to exponentially rising morbidity and
mortality worldwide. Apart from aggressive
quarantine and hygiene control measures, the
most effective way to inhibit SARS-CoV-2 spread is
a population-wide vaccination campaign. Since
the date of the introduction and overall
effectiveness of SARS-CoV-2 vaccines are not
known, alternative approaches for active
immunisation against SARS-CoV-2 are under
consideration. The role of Bacillus Calmette–
Guerin (BCG) vaccination in the prevention of
SARS-CoV-2 infection and in the epidemiology of
COVID-19 has been frequently implicated.1 BCG is
an attenuated Mycobacterium bovis strain, a
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species of the Mycobacterium tuberculosis
complex, and is used worldwide for vaccination
against M. tuberculosis. Interestingly, BCG appears
to have multiple effects. Thus, it was observed
that BCG immunisation could also induce a so-
called heterologous immune response against
viruses such as human papillomavirus, influenza A,
live yellow fever vaccine and hepatitis B (HBsAg)
as well as organisms such as Candida albicans
(C. albicans) and Staphylococcus aureus
(S. aureus).2–4
The adaptive component of heterologous
immunity is thought to originate from the
epitope similarity between distant microorganisms
coupled with the polyspecificity of T-cell and B-
cell responses. In this study, we decided to explore
whether BCG immunisation-induced heterologous
adaptive immunity could theoretically play a role
in the protection against SARS-CoV-2. We
compared the T-cell and B-cell epitopes of the
BCG strain Pasteur 1173P2 (BCG-Pasteur) with T-
cell and B-cell epitopes of SARS-CoV-2 and
identified numerous highly similar epitopes
between the two microorganisms.
RESULTS
General description of peptide similarity
between the BCG-Pasteur and SARS-CoV-2
proteomes
To explore the similarity of the BCG-Pasteur
proteome to other proteomes, we compared the
9-mer and 15-mer peptides of the BCG-Pasteur
proteome to 40 viral proteomes and the
C. albicans and S. aureus proteomes. We chose
the 9-mer and 15-mer peptide lengths as
characteristic lengths for MHC-I-restricted epitopes
and MHC-II-restricted epitopes/ linear B-cell
epitopes. Our data showed that the number of
both the 9-mer and 15-mer peptides with high
identity (≥ 67%) to BCG-Pasteur peptides was
strongly correlated with the proteome sizes of the
microorganisms (Figure 1a and b). In addition to
SARS-CoV-2, the comparison included RSV, HPV,
yellow fever virus, influenza A, HSV-1, C. albicans
and S. aureus. These pathogens served as positive
controls, as the prevalence/severity of the
infections caused have been shown to be reduced
by BCG vaccination and/or BCG-induced cross-
immunity was observed previously.2,4 These
pathogens, including SARS-CoV-2, correlate very
well and follow the trend between genome
length and the prevalence of similar peptides
across a wide range of proteome sizes.
Comparison of the similarity between BCG-Pasteur
proteome and the original SARS-CoV-2 or random
proteomes showed that the original SARS-CoV-2
proteome contained a significantly higher number
of similar 9-mer peptides than all of the 50
random proteomes. For the 15-mer peptides, the
SARS-CoV-2 proteome demonstrated higher
numbers of similar peptides than most of the
random proteomes (Figure 2a). Next, we explored
how the peptide length and degree of identity
between the peptide pairs influence the number
of similar peptides between the BCG-Pasteur and
SARS-CoV-2 proteomes (Figure 2b). Very large
numbers of 9-mer and 15-mer peptides with
limited (< 3 aa) identity were found but when
using ≥ 67% identity as a threshold level, the
numbers of 9-mer peptides with six or higher
identical amino acids were 40 352 and the
numbers of 15-mer peptides with 10 or more
identical amino acids were 24 (Figure 2b insets).
Identification of BCG-Pasteur epitopes that
are highly similar to the putative SARS-CoV-
2 T-cell epitopes
Firstly, we mapped the experimentally verified
SARS-CoV-2 T-cell MHC-I-restricted epitopes to the
BCG-Pasteur proteome using an identity threshold
of ≥ 67%. Further NetMHC 4.0 analysis identified
217 ‘strong binder’ BCG-Pasteur peptides that
could be presented by at least one representative
allele of an HLA-A or HLA-B supertype. A third
analysis step compared the BCG-Pasteur peptide-
associated HLA alleles with the associated HLA
allele(s) of the similar SARS-CoV-2 peptide. This
selection resulted in 112 BCG-Pasteur peptides
that are 1. highly similar to the MHC-I-restricted
SARS-CoV-2 epitope and 2. presented by an HLA
allele related to the same HLA supertype
(Figure 3a, Supplementary table 1). These 112
BCG-Pasteur peptides had a similar counterpart in
16 different SARS-CoV-2 proteins (Figure 3b)
resulting the multiple representation of SARS-
CoV-2 epitopes by BCG-Pasteur epitopes. SARS-
CoV-2 epitopes such as LLSAGIFGA, FLLPSLATV,
ALLADKFPV and LLLDRLNQL had 9, 8, 7 and 7
similar BCG-Pasteur peptide pairs, respectively. An
extreme example was the SARS-CoV-2 nsp05
protein epitope VLAWLYAAV which was the
single epitope of the nsp05 protein but had 23
BCG-Pasteur epitope counterparts with 66%
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identity and the 78% identical ALAWLVAAV
epitope. The 24 BCG-Pasteur epitope pairs of
VLAWLYAAV represented 23 different BCG-
Pasteur proteins. The best represented SARS-CoV-2
proteins were the nsp05, a chymotrypsin-like
protease (M pro) and the spike glycoprotein. A
similar analysis was performed for SARS-CoV-2
MHC-II-restricted T-cell epitopes but we found no
highly similar epitopes between the two
microorganisms, primarily due to the longer
length of most peptides presented via MHC-II to T
cells.
Figure 1. Exploration of peptide similarity between the Bacillus Calmette–Guerin (BCG)-Pasteur proteome and other proteomes. All possible 9-
mer and 15-mer BCG-Pasteur peptides were compared to the same-length peptides of a variety of 40 viral proteomes and the C. albicans and
Staphylococcus aureus proteomes, ranging in size from < 1e+3 to > 1e+6. (a) 9-mer peptides with ≥ 67% identity. (b) 15-mer peptides with
≥ 67% identity. Pearson correlation coefficients between the number of similar peptides and the proteome lengths are also shown. HPV, human
papillomavirus; HSV-1, herpes simplex virus-1; RSV, respiratory syncytial virus.
Figure 2. Exploration of peptide similarity between the Bacillus Calmette–Guerin (BCG)-Pasteur proteome and the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) proteome. (a) Comparison of the BCG-Pasteur proteome to the SARS-CoV-2 proteome and randomised
proteomes. 9-mer and 15-mer peptides of the BCG-Pasteur proteome were mapped to the SARS-CoV-2 proteome and 50 random proteomes
containing the same number and length proteins as the original SARS-CoV-2 proteome but with scrambled amino acid composition. The number
of 9-mer and 15-mer BCG-Pasteur peptides ≥ 67% identical to a SARS-CoV-2 peptide are shown. Interquartile range analysis of outliers identified
values higher than 40 222 as an outlier for 9-mer sequences and 30.25 for 15-mer sequences. According to this analysis, the SARS-CoV-2 9-mer
value (40 848) was an outlier, but the SARS-CoV-2 15-mer value (24) was not. Grubbs’ test for outliers was applied to calculate the significance
of the 40 848 value as an outlier. *P < 0.05. (b) Exploration of the identity between BCG-Pasteur peptides and SARS-CoV-2 peptides. 9-mer and
15-mer BCG-Pasteur peptides were mapped to the SARS-CoV-2 proteome. The number of BCG-Pasteur peptides with different level of identity
to a SARS-CoV-2 peptide is shown. Inset graphs show the occurrence of the 9-mer and 15-mer peptides with ≥ 67% identity.
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Figure 3. Similarity between MHC-I-restricted Bacillus Calmette–Guerin (BCG)-Pasteur and severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) T-cell epitopes. Individual SARS-CoV-2 MHC-I-restricted T-cell epitopes were compared with all the possible same-length peptides
of the BCG-Pasteur proteome. BCG-Pasteur peptides with identity of ≥ 67% were analysed with NetMHC 4.0 to identify epitopes. (a) Top-
ranked BCG-Pasteur epitopes with the highest similarity/ NetMHC %Rank to an epitope of a SARS-CoV-2 protein. The NetMHC %Rank which
corresponds to the predicted HLA binding affinity is shown (lower NetMHC %Rank value indicates stronger HLA binding). Note that the SARS-
CoV-2 epitope SEETGTLIV has two identical epitope counterparts from two BCG-Pasteur proteins. (b) Distribution of SARS-CoV-2 epitopes among
the viral proteins. The number of SARS-CoV-2 epitopes and the number of their similar BCG-Pasteur epitope counterparts are shown. SG, spike
glycoprotein.
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Identification of BCG-Pasteur epitopes that
are highly similar to the putative
SARS-CoV-2 B-cell epitopes
We applied a similar selection scheme as before to
identify highly similar BCG-Pasteur sequences with
the experimentally verified and putative SARS-
CoV-2 B-cell epitopes. We mapped the SARS-CoV-
2 B-cell epitopes to the BCG-Pasteur proteome
and collected the highly similar sequences
(≥ 62.5% identity). The similarity between SARS-
CoV-2 and BCG-Pasteur sequences ranged
between 62.5% and 100%. The identified BCG-
Pasteur sequences were further analysed for
potential antigenicity using the BepiPred 2.0 B-cell
epitope prediction method.5 BepiPred analysis
revealed that 690 BCG-Pasteur sequences were
located within a BCG-Pasteur protein region that
is likely to be recognised by antibodies
(Supplementary table 2). These 690 BCG-Pasteur
peptides were similar to 17 putative SARS-CoV-2
B-cell epitopes located in the nsp12, orf4
(envelope protein), orf5 (membrane glycoprotein),
orf9 (nucleocapsid) and the spike glycoprotein
(Figure 4a), indicating a high level of
representation of these SARS-CoV-2 B-cell
epitopes. As an example of a prevalent epitope,
the potential SARS-CoV-2 nucleocapsid epitope
LLPAAD had 290 similar and likely antigenic BCG-
Pasteur counterparts, including an identical
counterpart. The high similarity and the existence
of several similar shared BCG-Pasteur epitopes
with SARS-CoV-2 B-cell epitopes could therefore
lead to the induction of cross-specific antibodies.
Interestingly, the putative SARS-CoV-2 spike
epitope FGEVFNAT, which is located in the
receptor binding domain and is likely to elicit
neutralising antibodies, had five similar BCG-
Pasteur counterparts (Figure 4b and c).
CONCLUSION
We systematically mapped numerous SARS-CoV-2
epitopes to the BCG-Pasteur proteome to find
similar epitopes that might induce adaptive cross-
immunity and explain the protective qualities of
BCG vaccination against SARS-CoV-2. Our analysis
of similar peptides of BCG-Pasteur and other
proteomes revealed that the occurrence of
epitope similarity is strongly correlated to the
proteome sizes of the microorganisms. As
expected, the SARS-CoV-2 proteome behaved
similarly, indicating that the coexistence of cross-
immunity with BCG-Pasteur is likely not due to
exceptional similarity between these evolutionary
distant microorganisms. The fact that the SARS-
CoV-2 proteome contained higher number of
similar epitopes than all (9-mer) or most of (15-
mer) the random proteomes further supports that
the similarity does not arise by chance between
the two proteomes. Rather, short conservative
protein sequences exist even between these
distant microorganisms. The number of highly
similar peptides between the two proteomes
strongly depended on the length of the peptides.
Thus, the numbers of similar 9-mer peptide pairs
were 3 orders of magnitude higher than that of
the 15-mers. The immunological consequence of
these findings would be that the adaptive cross-
immunity between these microorganisms has a
higher chance to be induced between shorter
epitopes and are therefore inherently directed
towards a MHC-I-restricted T-cell response.
Alternatively, these data could reflect MHC-II-
restricted T-cell responses to shorter epitopes and
B-cell recognition of short linear epitopes or
smaller conformational epitopes. Our
immunological analyses of the similar peptides
supported the former possibility since we
identified 112 similar MHC-I-restricted T-cell
epitope pairs but did not identify similar MHC-II-
restricted epitopes. However, these findings do
not completely rule out MHC-II-restricted cross-
immunity between BCG and SARS-CoV-2, since
epitopes with low level of full-length sequence
similarity can indeed induce cross-immunity.6 We
found that SARS-CoV-2 B-cell epitopes having
BCG-Pasteur counterparts were present mostly in
structural proteins including the spike
glycoprotein, a dominant target for protective
antibodies. Among the 8 spike glycoprotein
epitopes which had similar BCG-Pasteur peptide
counterparts, one was located in the receptor
binding domain, the target of neutralising
antibodies.7
Overall, we have shown that there are shared T-
cell and B-cell epitopes between SARS-CoV-2 and
BCG-Pasteur which suggests that BCG-induced
immunity could influence the adaptive immune
response against SARS-CoV-2. Although this in
silico study has not demonstrated functional cross-
reactive immunity, our work does support the
further investigation of heterologous immunity
between BCG and SARS-CoV-2. The similar BCG-
Pasteur peptides identified in this study could be
used as a reference set to assist the evaluation of
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BCG-induced SARS-CoV-2-directed T-cell and B-cell
responses.
METHODS
Proteome comparison of BCG-Pasteur and
SARS-CoV-2
Severe acute respiratory syndrome-CoV-2 protein sequences
were compared to the BCG-Pasteur proteome
(M. tuberculosis variant bovis BCG p-1173P2
(GCF_000009445.1)). The following SARS-CoV-2 protein
sequences were used: nsp1 (YP_009742608), nsp2
(YP_009742609), nsp3 (YP_009742610), nsp4
(YP_009742611), nsp5 (YP_009742612), nsp6
(YP_009742613), nsp7 (YP_009742614), nsp8
(YP_009742615), nsp9 (YP_009742616), nsp10
(YP_009742617), nsp11 (YP_009725312), nsp12
(YP_009725307), nsp13 (YP_009725308), nsp14
(YP_009725309), nsp15 (YP_009725310), nsp16
(YP_009725311), spike glycoprotein (YP_009724390), ORF3a
(YP_009724391), ORF4 (YP_009724392), ORF5
Figure 4. Similarity between Bacillus Calmette–Guerin (BCG)-Pasteur and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) B-cell
epitopes. (a) Individual SARS-CoV-2 B-cell epitopes (putative and experimentally verified) were compared with all the possible same-length
peptides of the BCG-Pasteur proteome. BCG-Pasteur proteins containing the highly similar peptides (≥ 62.5% identity) were analysed with
BepiPred 2.0 to identify putative B-cell epitopes. (b) Localisation of the SARS-CoV-2 B-cell epitope FGEVFNAT (red) in the receptor binding
domain (turquoise) of the homotrimer SARS-CoV-2 spike glycoprotein (side view and top view). (c) FGEVFNAT and the similar BCG-Pasteur B-cell
epitopes identified. SG, spike glycoprotein.
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(YP_009724393), ORF6 (YP_009724394), ORF7a
(YP_009724395), ORF7b (YP_009725318), ORF8b
(YP_009724396), ORF9 (YP_009724397), ORF10
(YP_009725255). For sequence comparison, the previously
described sequence identity measure was used.6 BCG-
Pasteur and SARS-CoV-2 peptide pairs that shared a ≥ 67%
identity in their peptide sequences were collected. The
same identity measure was used to compare the BCG-
Pasteur proteome to 40 viral proteomes and the C. albicans
and S. aureus proteomes. The same identity measure was
used to compare the BCG-Pasteur proteome to 50 randomly
generated proteomes consisting of same number of
peptides with the same amino acid compositions but
scrambled order the SARS-CoV-2 protein sequences used
before. To identify whether the SARS-CoV-2 proteome
contained more similar peptides than the random
proteomes, two methods were applied: 1, Interquartile
range (IQR, IQR = Q3  Q1) based outlier detection (Q1:
first quartile of the dataset , Q3: third quartile of the
dataset), which marks data points as outlier, if a data point
is above Q3 + 1.5*IQR; 2, Normal distribution of the data
was verified using the Shapiro–Wilk normality test, and
then, Grubbs’ test was applied to test whether the
maximum value was an outlier at the 0.05 significance
level.
Mapping the experimentally verified SARS-
CoV-2 T-cell and B-cell epitopes to the BCG-
Pasteur proteome
The experimentally verified SARS-CoV-2 T-cell and B-cell
epitopes (linear, human, positive T-cell assays, MHC-I
restricted and MHC-II restricted) were downloaded from
the Immune Epitope Database. Due to the low number of
MHC-II-restricted SARS-CoV-2 T-cell and B-cell epitopes,
experimentally verified SARS-CoV T-cell and B-cell epitopes
with identical sequence to SARS-CoV-2 were also included
in the analysis as putative SARS-CoV-2 epitopes. SARS-CoV-
2 epitopes were compared to the BCG-Pasteur proteome
using the above-mentioned identity measure. BCG-Pasteur
peptides with identity (same amino acid at the same
position) of ≥ 67% were used for further T-cell epitope
selection, because recently it was showed that if there is a
≥ 67% identity between a SARS-CoV-2 epitope and
another coronavirus epitope than there is a 57% chance
that adaptive cross-immunity can be observed.6 Similar
threshold was observed in SARS-CoV-2 MHC-1-restricted T-
cell cross immune responses.8 The threshold of the
identification of cross binding linear B-cell epitopes has
not been described, and therefore, an identity threshold
similar to the T-cell analysis (≥ 62.5%) was used in this
study. BCG-Pasteur peptides similar to MHC-I-restricted
epitopes were further analysed with NetMHC 4.0
software9 using predefined alleles representative of the
HLA-A and HLA-B supertypes. BCG-Pasteur peptides similar
to MHC-II-restricted SARS-CoV-2 peptides were analysed
with NetMHCII 2.3.10 The identified ‘strong binder’
epitopes were collected (threshold for strong binders:
≤ 0.5% Rank for NetMHC 4.0 and ≤ 2% Rank for
NetMHCII 2.3). BCG-Pasteur proteins with identity of
≥ 62.5% to a SARS-CoV-2 B-cell epitopes were further
analysed with the BepiPred 2.0 software.5 Peptides that
were located entirely in an epitope region by BepiPred
2.0 were collected. 3D molecular surface model of SARS-
CoV-2 spike protein homotrimer was created with the
Maestro GUI of the Schr€odinger program suit (Schr€odinger
Inc., New York, NY, USA) using the 6X29 pdb structure
from the Protein Data Bank crystallographic database
(www.rcsb.org).
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